Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients

[1]  B. Seal,et al.  Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. , 2021, JAMA oncology.

[2]  Xiaobing Yang,et al.  Prognostic significance of programmed cell death‐ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta‐analysis , 2021, Cancer medicine.

[3]  Amy Davis,et al.  Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection , 2021, Clinical research.

[4]  I. Abdulkader,et al.  Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab , 2021, Molecular oncology.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  M. Millward,et al.  Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer , 2021, Translational lung cancer research.

[7]  Zhengxu Fang,et al.  Regulatory mechanisms and clinical significance of vimentin in breast cancer. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Kaitai Zhang,et al.  Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis , 2021, Oncoimmunology.

[9]  M. Millward,et al.  Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2020, Cells.

[10]  S. Agelaki,et al.  Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy , 2020, Cancers.

[11]  Wei Wu,et al.  Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer , 2020, BMC Pulmonary Medicine.

[12]  V. Durieux,et al.  Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept , 2020, Frontiers in Medicine.

[13]  R. Herbst,et al.  Frontline immunotherapy for NSCLC — the tale of the tail , 2020, Nature Reviews Clinical Oncology.

[14]  A. Varray,et al.  Specific motor cortex hypoexcitability and hypoactivation in COPD patients with peripheral muscle weakness , 2020, BMC Pulmonary Medicine.

[15]  M. Daidone,et al.  A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer , 2019, International journal of cancer.

[16]  Laura Keller,et al.  Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells , 2019, Nature Reviews Cancer.

[17]  V. Bobek,et al.  Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer , 2019, In Vivo.

[18]  G. Kallergi,et al.  CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? , 2019, Therapeutic advances in medical oncology.

[19]  M. Tiemann,et al.  Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors , 2019, Cancers.

[20]  J. Kaifi,et al.  PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer , 2019, Cancers.

[21]  Liyuan Wei,et al.  Epithelial‑mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC. , 2018, Molecular medicine reports.

[22]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature reviews. Molecular cell biology.

[23]  James B. Freeman,et al.  Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma , 2018, JCO precision oncology.

[24]  O. Gires,et al.  Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells , 2017, Scientific Reports.

[25]  K. Pantel,et al.  Characterization of single circulating tumor cells , 2017, FEBS letters.

[26]  F. Portillo,et al.  EMT: Present and future in clinical oncology , 2017, Molecular oncology.

[27]  D. Berney,et al.  The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis , 2017, Clinical Cancer Research.

[28]  David S. K. Lu,et al.  Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[29]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[30]  Leonie L. Zeune,et al.  Improving the CellSearch® system , 2016, Expert review of molecular diagnostics.

[31]  Yi-huan Luo,et al.  Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases , 2016, PloS one.

[32]  S. Stefansson,et al.  Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining , 2016, Scientific Reports.

[33]  D. Beebe,et al.  High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1 , 2016, PloS one.

[34]  P. Robson,et al.  Tumor-derived circulating endothelial cell clusters in colorectal cancer , 2016, Science Translational Medicine.

[35]  C. Zappa,et al.  Non-small cell lung cancer: current treatment and future advances. , 2016, Translational lung cancer research.

[36]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[37]  N. Stoecklein,et al.  Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution , 2016, Expert review of molecular diagnostics.

[38]  Sumitra Mohan,et al.  Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. , 2016, The Analyst.

[39]  V. Wang,et al.  A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay , 2015, PloS one.

[40]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[41]  John Hines,et al.  Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System , 2015, PloS one.

[42]  K. Pantel,et al.  Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer , 2015, Front. Oncol..

[43]  Hongbing Shen,et al.  Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application , 2015, PloS one.

[44]  Jia Zhou,et al.  Circulating Tumor Cells in Lung Cancer: Detection Methods and Clinical Applications , 2015, Lung.

[45]  Junjiang Fu,et al.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer , 2014, Tumor Biology.

[46]  C. Marquette,et al.  Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer , 2014, British Journal of Cancer.

[47]  D. Thickett,et al.  Epithelial–mesenchymal transition in lung development and disease: does it exist and is it important? , 2013, Thorax.

[48]  Z. Werb,et al.  Circulating Tumor Cells , 2013, Science.

[49]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[50]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[51]  Caroline Dive,et al.  Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  D. Planchard,et al.  Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer , 2011, British Journal of Cancer.

[53]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  C. Marquette,et al.  Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  W. Gorczyca,et al.  Immunophenotypic pattern of myeloid populations by flow cytometry analysis. , 2011, Methods in cell biology.

[56]  P. Bayer,et al.  Anticytokeratins are a potential source of false‐positive indirect immunofluorescence assays for C‐ANCA , 1998, Journal of clinical laboratory analysis.